FALLOPIAN TUBE CARCINOMA
Clinical trials for FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug cocktail shows promise in slowing return of ovarian cancer
Disease control OngoingThis phase 2 study tests whether combining two oral drugs, olaparib and cediranib, can help control recurrent ovarian, peritoneal, or fallopian tube cancer. About 70 participants with high-grade serous or endometrioid cancers are enrolled. The goal is to see if the combination ca…
Matched conditions: FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have …
Matched conditions: FALLOPIAN TUBE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental antibody boosts chemo in ovarian cancer trial
Disease control OngoingThis phase 2 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps control advanced ovarian, fallopian tube, or peritoneal cancer better than chemo alone. About 88 women with newly diagnosed stage III or …
Matched conditions: FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ovarian cancer hope: new antibody combo aims to delay disease worsening
Disease control OngoingThis Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…
Matched conditions: FALLOPIAN TUBE CARCINOMA
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Heated chemotherapy during surgery may delay ovarian cancer return
Disease control OngoingThis phase 3 trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help people with advanced ovarian cancer live longer without the disease coming back. About 362 participants will either receive standard surgery alone or surgery plus the hea…
Matched conditions: FALLOPIAN TUBE CARCINOMA
Phase: PHASE3 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Ovarian cancer trial hopes immunotherapy can buy more time
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has become resistant to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian…
Matched conditions: FALLOPIAN TUBE CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Vaccine-Immunotherapy cocktail shows promise in ovarian cancer trial
Disease control OngoingThis phase 2 study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with an experimental vaccine called DPX-Survivac and low-dose chemotherapy (cyclophosphamide) can shrink tumors in people with advanced ovarian, peritoneal, or fallopian tube cancer. The va…
Matched conditions: FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 26, 2026 18:48 UTC
-
Mushroom extract tested to ease chemo side effects in ovarian cancer
Symptom relief OngoingThis pilot study tests whether a supplement called AHCC, made from cultured mushroom mycelia, can improve quality of life for ovarian cancer patients receiving standard chemotherapy. About 20 participants will take either AHCC or a placebo during their treatment. The main goal is…
Matched conditions: FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Simple home workouts tested to boost strength before ovarian cancer surgery
Symptom relief OngoingThis pilot study tests whether a personalized home exercise program is practical and helpful for women with advanced ovarian cancer who are receiving chemotherapy before surgery. Twenty-two participants will follow daily exercises and weekly coaching until their operation. The ma…
Matched conditions: FALLOPIAN TUBE CARCINOMA
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Can mitochondrial energy predict resilience in older cancer patients?
Knowledge-focused TerminatedThis study looks at whether older adults with gynecologic cancer are willing to complete physical and cognitive tests before and after treatment. Researchers will also take small muscle and blood samples to study how cell energy relates to resilience. The goal is to see if this k…
Matched conditions: FALLOPIAN TUBE CARCINOMA
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Massive biobank aims to unlock Cancer's secrets
Knowledge-focused OngoingThis study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…
Matched conditions: FALLOPIAN TUBE CARCINOMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC